These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 20622080

  • 1. The effects of biofeedback in diabetes and essential hypertension.
    McGrady A.
    Cleve Clin J Med; 2010 Jul; 77 Suppl 3():S68-71. PubMed ID: 20622080
    [Abstract] [Full Text] [Related]

  • 2. Treatment of metabolic syndrome.
    Wagh A, Stone NJ.
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):213-28. PubMed ID: 15151470
    [Abstract] [Full Text] [Related]

  • 3. ESH-ESC guidelines for the management of hypertension.
    Erdine S, Ari O, Zanchetti A, Cifkova R, Fagard R, Kjeldsen S, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, Staessen J, van Zwieten P, Waeber B, Williams B.
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [Abstract] [Full Text] [Related]

  • 4. Prevention of diabetes development in those with the metabolic syndrome.
    Tupper T, Gopalakrishnan G.
    Med Clin North Am; 2007 Nov; 91(6):1091-105, viii-ix. PubMed ID: 17964911
    [Abstract] [Full Text] [Related]

  • 5. The management of pre-hypertension and metabolic syndrome.
    Rossi R, Nuzzo A, Modena MG.
    Minerva Cardioangiol; 2009 Dec; 57(6):723-31. PubMed ID: 19942844
    [Abstract] [Full Text] [Related]

  • 6. Metabolic syndrome: diabetes and cardiovascular disease.
    Gupta S, Gupta BM.
    Indian Heart J; 2006 Dec; 58(2):149-52. PubMed ID: 18989060
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of biofeedback in the treatment of borderline essential hypertension.
    Blanchard EB, Miller ST, Abel GG, Haynes MR, Wicker R.
    J Appl Behav Anal; 1979 Dec; 12(1):99-109. PubMed ID: 468751
    [Abstract] [Full Text] [Related]

  • 8. Lifestyle modifications to prevent and control hypertension. 7. Recommendations on stress management. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada.
    Spence JD, Barnett PA, Linden W, Ramsden V, Taenzer P.
    CMAJ; 1999 May 04; 160(9 Suppl):S46-50. PubMed ID: 10333853
    [Abstract] [Full Text] [Related]

  • 9. Coronary risk factor reduction through biofeedback-aided relaxation and meditation.
    Patel C, Carruthers M.
    J R Coll Gen Pract; 1977 Jul 04; 27(180):401-5. PubMed ID: 330850
    [Abstract] [Full Text] [Related]

  • 10. The future of antihypertensive treatment.
    Israili ZH, Hernández-Hernández R, Valasco M.
    Am J Ther; 2007 Jul 04; 14(2):121-34. PubMed ID: 17414579
    [Abstract] [Full Text] [Related]

  • 11. Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy.
    López-Candales A.
    J Med; 2001 Jul 04; 32(5-6):283-300. PubMed ID: 11958275
    [Abstract] [Full Text] [Related]

  • 12. Magnesium in hypertension, cardiovascular disease, metabolic syndrome, and other conditions: a review.
    Champagne CM.
    Nutr Clin Pract; 2008 Jul 04; 23(2):142-51. PubMed ID: 18390781
    [Abstract] [Full Text] [Related]

  • 13. A work in progress: the metabolic syndrome.
    Luchsinger JA.
    Sci Aging Knowledge Environ; 2006 Jun 28; 2006(10):pe19. PubMed ID: 16807483
    [Abstract] [Full Text] [Related]

  • 14. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population.
    Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, Giannattasio C, Grassi G, Sega R.
    J Hypertens; 2008 Aug 28; 26(8):1602-11. PubMed ID: 18622239
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of relaxation techniques in hypertensive patients.
    Aivazyan TA, Zaitsev VP, Salenko BB, Yurenev AP, Patrusheva IF.
    Health Psychol; 1988 Aug 28; 7 Suppl():193-200. PubMed ID: 3072179
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Factors predicting the development of metabolic syndrome and type II diabetes against a background of hypertension.
    Lim HS, Lip GY, Beevers DG, Blann AD.
    Eur J Clin Invest; 2005 May 28; 35(5):324-9. PubMed ID: 15860044
    [Abstract] [Full Text] [Related]

  • 18. Non-pharmacological management of essential hypertension.
    Anand MP.
    J Indian Med Assoc; 1999 Jun 28; 97(6):220-5. PubMed ID: 10645695
    [Abstract] [Full Text] [Related]

  • 19. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study.
    Ilanne-Parikka P, Eriksson JG, Lindström J, Peltonen M, Aunola S, Hämäläinen H, Keinänen-Kiukaanniemi S, Laakso M, Valle TT, Lahtela J, Uusitupa M, Tuomilehto J, Finnish Diabetes Prevention Study Group.
    Diabetes Care; 2008 Apr 28; 31(4):805-7. PubMed ID: 18184907
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.